LEXINGTON, Mass., June 17,
2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN),
an immuno-oncology (I-O) company with
a pipeline of immune checkpoint antibodies,
adoptive cell therapies and cancer
vaccines, announced today that Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics,
and Dr. Marc Van Dijk, Chief
Technology Officer of Agenus and AgenTus Therapeutics, will
participate in a panel discussion on Cell Therapy at the Raymond
James Virtual Human Health Innovation Conference on June 17, 2020.
Date: Wednesday, June 17, 2020
Time: 12:00 PM –
12:50 PM ET
Title: Cell Therapy: Promise of the Next Generation
– Cell Therapy has become a fast-changing field after becoming
a powerful clinical therapy for late line cancer patients with the
approval of the first generation CD19+ CAR T cell treatments
(Yescarta and Kymriah). Participants in the panel include AgenTus
Therapeutics, a biotech company and subsidiary of Agenus Inc.
developing new cancer treatments, including AGENT-797, an early
unmodified allogeneic iNKTcell therapy, Magenta Therapeutics, a
cell therapy company developing novel cell therapies including
MGTA-456, a stem -cell production therapy, and SQZ Biotechnologies
Company, a biotech company developing oncology drugs including APC
HPV, an autologous based therapy for several types of cancer.
Agenus Inc.
Walter
Flamenbaum, M.D. – Chief Executive Officer, AgenTus
Therapeutics
Marc van Dijk, Ph.D. – Chief
Technology Officer, Agenus
Allogene Therapeutics
Rafael
Amado, M.D. – EVP of Research and Development and Chief
Medical Officer
Obsidian Therapeutics
Paul
Wooton – Chief Executive Officer
Ryan Daws – Chief Financial
Officer
SQZ Biotechnologies
Armen Sharei– Chief Executive
Officer
Teri Loxam – Chief Financial
Officer
Rebecca Cohen – Investor Relations
Officer
ZIOPHARM Oncology, Inc.
Laurence Cooper – Chief Executive Officer
About AgenTus Therapeutics, Inc.
AgenTus
Therapeutics is a biopharmaceutical company focused on the
discovery, development, and commercialization of breakthrough
allogeneic iNKT cells in the unmodified and modified with
engineered receptors, such as T cell receptors (TCRs) and Chimeric
Antigen Receptors (CARs), designed to supercharge the human immune
system cells to seek and destroy cancer. AgenTus also aims to
advance adoptive cell therapy formats which would enable
off-the-shelf living drugs. AgenTus has locations
in Lexington, MA and Cambridge, UK. For more
information, please
visit www.agentustherapeutics.com.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and twitter.
Contact:
Agenus Inc.
Jennifer
Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-and-agentus-to-participate-in-a-panel-presentation-on-cell-therapy-at-the-raymond-james-virtual-human-health-innovation-conference-301078846.html
SOURCE Agenus Inc.